FDA Okays Low-Sodium Treatment Option for Narcolepsy FDA Okays Low-Sodium Treatment Option for Narcolepsy
The novel drug Xywav is an oxybate product with a unique composition that results in 92% less sodium than sodium oxybate (Zyrem).FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news
More News: Brain | Drugs & Pharmacology | Narcolepsy | Neurology | Neurosurgery | Sleep Medicine | Sodium